BOSTON -- Genzyme Corp. and Sanofi-Aventis could announce a merger deal within the next week or two, Reuters reported Monday, citing sources familiar with the matter. Reuters added that the two parties have already agreed on the potential deal's structure. Early Monday, Genzyme announced that it will allow Sanofi to conduct due diligence on its books. Sanofi has bid $69 a share for Genzyme, which its board has rejected as too low. In particular, Genzyme has argued that Sanofi's offer does not fully recognize the value of its multiple sclerosis drug candidate alemtuzumab. The companies have said they are considering adding a contingent value right to the deal that would focus on alemtuzumab's potential value.
Copyright © 2011 MarketWatch, Inc.